Zoledronic acid inhibits macrophage SOCS3 expression and enhances cytokine production by Scheller, Erica L. et al.
Zoledronic Acid Inhibits Macrophage SOCS3 Expression and
Enhances Cytokine Production
Erica L. Scheller,1 Kurt D. Hankenson,2 Jayne S. Reuben,3 and Paul H. Krebsbach1*
1Department of Biologic and Materials Sciences, University of Michigan School of Dentistry, Ann Arbor,
Michigan 48109
2Department of Animal Biology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia,
Pennsylvania 19104
3Baylor College of Dentistry, Dallas, Texas 75246
ABSTRACT
Suppressor of cytokine signaling-3 (SOCS3) has multiple functions including inhibition of Janus kinase (Jak) activity, regulation of protein
degradation, and suppression of cytokine signaling. SOCS3 modulates macrophage response to cytokines such as IL-6 and leptin that are
systemically induced in obesity. Obesity is a suspected risk factor for SOCS3-related pathology such as rheumatoid arthritis and Crohn’s
disease as well as zoledronic acid (ZA)-induced osteonecrosis of the jaw (ONJ). Thus, understanding the ability of bisphosphonates tomodulate
SOCS3 is necessary to qualify their contribution to these disorders. ONJ occurs in up to 10% of patients using intravenous bisphosphonates
and has an unknown pathogenesis that may be linked to decreased bone turnover, altered vascularity, bacterial invasion, and compromised
wound healing. Given the increased risk of ONJ with obesity and importance of macrophages in wound healing, we hypothesized that amino-
bisphosphonates could contribute to the pathogenesis of ONJ by regulating macrophage responses to cytokines such as leptin and IL-6. We
report that ZA is a novel inhibitor of SOCS3 in primary macrophages and human ONJ biopsy specimens. Inhibition of SOCS3 by ZA resulted in
significant increases in IL-6 production. SOCS3 transcription is regulated by nuclear accumulation of phosphorylated-Stat3 (P-Stat3). We
found that ZA decreased phosphorylation of Stat3 in a mevalonate-pathway dependent manner. However, restoration of P-Stat3 was
not sufficient to correct SOCS3 inhibition. We propose that disruption of macrophage SOCS3 expression by amino-bisphosphonates such as
ZA may be a novel contributor to inflammatory phenotypes in obesity and the pathogenesis of ONJ. J. Cell. Biochem. 112: 3364–3372,
2011.  2011 Wiley Periodicals, Inc.
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S uppressor of Cytokine Signaling-3 (SOCS3), a member of theSOCS family of proteins, has multiple domain-specific
functions that include inhibition of Janus kinase (Jak) activity,
competition with signal transducer and activator of transcription
(Stat) proteins, regulation of protein degradation, and suppression of
cytokine signaling [Piessevaux et al., 2008]. Expression of SOCS3 is
induced by extracellular binding proteins such as interleukin 6 (IL-
6), IL-10, interferon gamma (IFN-y), bacterial lipopolysaccharide
(LPS), and leptin. Complete deficiency of SOCS3 in mice is lethal due
to placental defects [Yasukawa et al., 2003], however, conditional
deletion has revealed a wide role for SOCS3 in cells and tissues
including macrophages [Ohishi et al., 2005], the central nervous
system [Mori et al., 2004], T cells [Kinjyo et al., 2006], the pancreas
[Mori et al., 2007], and the liver [Ogata et al., 2006]. Alterations in
SOCS3 protein levels may play a significant role in the pathogenesis
of inflammatory diseases including rheumatoid arthritis [Isomaki
et al., 2007], inflammatory bowel disease [Suzuki et al., 2001], and
Crohn’s disease [Lovato et al., 2003].
Zoledronic acid (ZA) is a commonly used amino-bisphosphonate
medication that is approved in the United States for treatment of
Paget’s disease, postmenopausal osteoporosis, multiple myeloma,
and bone metastases from solid tumors [Ibrahim et al., 2003].
Additional off-label uses such as treatment of osteoarthritis and
rheumatoid arthritis are growing increasingly popular [Jarrett et al.,
2006; Zoler, 2010]. ZA is highly potent with a half-life potentially
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initial administration [Khan et al., 1997]. The compound is then
gradually released during bone remodeling. This generates potential
for long-term systemic effects and has been linked to complications
such as osteonecrosis of the jaw (ONJ). ONJ is diagnosed when a
patient with a history of bisphosphonate use and without previous
radiation treatment presents with exposed bone in the oral cavity
that fails to heal after 8 weeks [Novince et al., 2009]. A survey of
over 700,000 medical claims revealed that those taking IV
bisphosphonates were at a four to sixfold increased risk of requiring
jaw surgery due to inflammatory changes [Cartsos et al., 2008] and a
survey of cancer patients specifically taking ZA found a 30-fold
increase in risk of ONJ [Wessel et al., 2008].
In patients taking ZA, obesity is also a risk factor for development
of ONJ [Wessel et al., 2008]. Obesity has been linked to significant
increases in systemic markers of inflammation such as c-reactive
protein and circulating inflammatory cytokines such as leptin, IL-6,
and TNF-a [Considine et al., 1996; Das, 2001; Fontana et al., 2007].
Obesity is also a suspected risk factor for SOCS3-related
inflammatory disorders such as rheumatoid arthritis and Crohn’s
disease [Voigt et al., 1994; Mendall et al., 2011]. Given the
increasing prevalence of amino-bisphosphonate use, understanding
the ability of these compounds to modulate inflammation and
macrophage cytokine production is necessary to qualify their
contribution to these disorders.
The main function of amino-bisphosphonates such as ZA is to
reduce osteoclast activity both by induction of osteoclast apoptosis
[Sudhoff et al., 2003] and inhibition of osteoclast maturation
through blockage of protein prenylation and geranyl-geranylation
in myeloid precursor cells [Coxon et al., 2000; Russell et al., 2008].
Although the macrophage and the osteoclast originate from a
common precursor, much less is known about the effects of
bisphosphonates on macrophage gene expression. Macrophages
play an important role in the early phase of wound healing. In
addition to the phagocytosis of debris and bacteria, macrophages
release cytokines that promote proliferation of fibroblasts and
endothelial cells. Some studies have suggested that reduced
macrophage infiltration may, in part, be responsible for the
increased rate of healing in oral mucosa compared to dermal sites
[Szpaderska et al., 2003]. We previously demonstrated that
macrophages are present in human ONJ biopsy specimens with a
trend toward increased macrophage numbers in patients with IV
bisphosphonate-induced ONJ [Scheller et al., 2011]. Thus, under-
standing the mechanisms by which bisphosphonates regulate
macrophage functions, such as cytokine secretion, may provide
insight into the pathogenesis of ONJ and lead to discovery of new
therapeutic targets. Given the increased risk of ONJ with obesity and
the importance of macrophages in wound healing, we hypothesized
that amino-bisphosphonates could contribute to the progression of
ONJ and other inflammatory disorders by regulating macrophage
responses to systemic cytokines such as leptin and IL-6.
MATERIALS AND METHODS
TRANSGENIC MICE
All procedures were approved by the University Committee on the
Use and Care of Animals. Mice with the coding sequence for exon17
of the long-form leptin receptor (ObRb) flanked by loxP were
obtained from Dr. Martin Myers (University of Michigan) with
permission of Dr. Streamson Chua (Columbia University) [McMinn
et al., 2004]. Mice with germline transmission of the recombined
floxed region and inactivation of leptin receptor signaling were used
in our study and are referred to as knock-out (KO) mice. ObRb
transgenic s/s (point mutation at tyrosine 1138) and l/l (point
mutation at tyrosine 985) mice were the generous gift of Dr. Peter
Mancuso (University of Michigan) and are also available from
Jackson Labs (Stock No. 008518 and 008385). Genotyping of s/s, l/l,
and ObRb KO mice was performed from tail biopsy as described
previously [Bates et al., 2003; McMinn et al., 2004; Bjornholm et al.,
2007]. Recombination and deletion of the loxP flanked allele was
determined using a three-primer system designed by McMinn et al.
[2004].
CELL CULTURE
Human. Primary human bone marrow macrophages (hBMMs) were
differentiated from primary marrow of iliac crest specimens (60-
year old male) obtained with University of Michigan Institutional
Review Board (IRB) approval. Fragments were washed extensively
with PBS and marrow suspension processed with Lympholyte1
Mammal gradient cell separation media (Cedarlane1 Laboratories,
Cat:CL5110) to remove dead cells and erythrocytes. Briefly, 4ml cell
suspension was layered on 3ml Lympholyte1 and centrifuged at
800g for 20min at room temperature. The lymphocyte layer was
harvested with a Pasteur pipet and washed three times in media.
Cells were plated in macrophage growth medium (a-Modified
Eagle’s Medium (a-MEM; Invitrogen/Gibco), 10% FBS (Gibco, Lot
no.451459), 100U/ml penicillin, 100mg/ml streptomycin sulfate
(Gibco Cat:15140)) at a density of 700,000 cells/cm2 in 100 ng/ml
recombinant human macrophage colony stimulating factor (M-CSF)
(Peprotech, Cat:300-25). Media was replenished after 2 days. At
day 4 serum free mediaZA was added overnight before
stimulation with 50 ng/ml IL-6 (Peprotech, Cat:200-06) for 5 h.
Mouse. Bone marrow macrophages (BMMs) were generated by
plating the total marrow from two mice (femora, tibiae, and humeri)
to 36-wells of two 24-well plates for ELISA or five 60mm dishes for
Western blot analysis. Cells were derived in macrophage growth
medium plus 70 ng/ml M-CSF (Peprotech, Cat:315-02)) for 2–3 days.
Primary BMMs were serum starved in the presence of ZA ((Novartis,
Zometa1) overnight (16–18 h) before treatment with 100 nM
recombinant mouse leptin (R&D Systems, Cat:398-LP-01M), 20%
fetal bovine serum, or 25 ng/ml IL-6 (PeproTech, Cat:216-16) for 1 h
for qPCR, 3 h for Western blot analysis, or 24 h for ELISA. Cells were
treated with 5–10mM trans,trans-Farnesol (FOH) (Sigma:277541) or
geranylgeraniol (GGOH) (Sigma:G3278) where indicated.
ELISA
BMMs were plated in 24-well plates, six wells per data point per
experiment. All experiments were repeated at least twice. After
3 days of BMM differentiation, cells were serum starved in the
presence of 107–105M ZA overnight. Subsequently, 250 ul of
a-MEMþ 0.5% BSA (Sigma, Cat:A8806) containing fresh ZA and
100 nM Leptin as added as indicated. Supernatant was harvested
after 24 h and stored at 808C until analyzed. Post-supernatant
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removal, genomic DNA was harvested using the QIAGEN DNeasy kit
(Cat:69506) by adding PBS, proteases, and buffer directly to each
well followed by incubation of the whole plate at 558C. Harvested
DNA was quantified using a UV spectrophotometer at 260 nm. Ratio
of 260 nm to 280 nm absorbance was greater than 1.4 for sample
acceptance. Ten to 25ml of supernatant was analyzed with an IL-6
ELISA kit (R&D Systems, Cat:M6000B). Results from each well were
normalized to total genomic DNA.
WESTERN BLOT ANALYSIS
Protein was harvested using NP-40 lysis buffer (10% glycerol, 1%
NP-40, 50mM Tris pH 7.4, 200mM NaCl, 2mMMgCl2, 1mM PMSF,
1 Protease Inhibitor Cocktail (Sigma Cat:P8340)). Cells were
collected and pelleted in 1ml ice cold PBS at 48C. Cell pellets were
resuspended in 25–50ml of lysis buffer, incubated for 30min on ice,
centrifuged at 13,000 rpm for 10min, and supernatant harvested.
Protein concentration was measured at 595 nmwith Bio-Rad protein
assay dye concentrate (Cat:500-0006). Protein extracts (30–80mg)
were boiled in 2 SDS sample buffer 5min and separated on a 12%
Tris-HCl polyacrylamide gel (Bio-Rad). Protein was transferred to
PVDF membranes using a wet transfer system (Bio-Rad Cat:170-
3930). Membranes were blocked in 5%milk (Stat3, P-Stat3, GAPDH;
Bio-Rad, Cat:170-6404) or 5% BSA (SOCS3, Sigma, Cat:A7906) 1 h
and probed overnight with 1:1,000 P-Stat3 (Cell Signaling:9131) or
1:1,000 SOCS3 (Cell Signaling:2923) and stripped and re-probed the
next day with 1:1,000 Stat3 (Cell Signaling:9132) and/or 1:1,000
GAPDH (Chemicon1 International:MAB374). Signals were ampli-
fied with 1:3,000 HRP-conjugated secondary antibody (Santa Cruz
Biotechnology) and SuperSignal1 West Pico Chemiluminescent
Substrate (Thermo Scientific, Pierce Product) and developed using
film exposure.
HUMAN TISSUE COLLECTION
Biopsies were accessioned with University of Michigan IRB
approval. Biopsies were identified as described previously [Scheller
et al., 2011] and assigned to one of two groups, no BP history
(control) or ONJ. H&E stained slides of all cases were examined to
ensure that each specimen contained epithelium and connective
tissue. Histological identification of non-vital bone with associated
bacterial colonies, consistent with osteonecrosis, was also required.
IMMUNOFLUORESCENCE
Cells were fixed for 5min in methanol at 208C before PBS wash
and permeabilization with 1% Triton-X-100 in PBS. Cells were
blocked in PBSþ 2.5% goat serumþ 2.5% donkey serumþ 0.1%
Triton-X-100 for 30min. CD68 primary antibody (1:500, AbCa-
m:ab955) was added in 1:10 diluted block for 1 h and after washing
signal was amplified with secondary antibody (1:500 Donkey anti-
mouse CyTM3, Jackson ImmunoResearch) for 45min. Nucleic acids
were visualized with DAPI.
IMMUNOHISTOCHEMISTRY
Immunohistochemistry was performed as described previously
[Scheller et al., 2011]. Formalin-fixed sections were deparaffinized
in xylene and rehydrated. Antigen retrieval was performed in pH 6.0
citrate buffer. Endogenous peroxidase was quenched in 3%
hydrogen peroxide for 30min followed by permeabilization in
0.1% Triton-X-100 in PBS. Slides were blocked with 2.5% normal
horse serum. Primary antibodies were added overnight at 48C: CD68
(1:500, Abcam:ab955) and SOCS3 (1:500, Abcam:ab16030). Signal
was amplified with ImmPRESS reagent (VectorLabs:MP-7500) and
imaged with ImmPACT DAB substrate (VectorLabs:SK-4105). Slides
were counterstained with hematoxylin. Serial sections were stained
for CD68 and SOCS3. Comparison was performed by generating a
representative image composite of all CD68 or SOCS3 stained
sections to ensure identical analysis of all images (40 magnifica-
tion), images were then processed with Adobe Photoshop CS3 by
using select!color range!reds to remove background blue
hematoxylin staining. The resulting composite was thresholded
with ImageJ (Scion Corp., Frederick, MD) and total pixel density of
stain per total field size of each specimen recorded. Results are
expressed as the ratio of SOCS3 stain density to CD68 stain density
in percent.
PCR
Total RNA was extracted from primary BMMs using TRIzol reagent
(Invitrogen). Total RNA (0.6mg) was converted to cDNA using the
SuperScript1 III First-Strand Synthesis SuperMix Kit (Invitro-
gen:11752). Resulting cDNA was diluted 1:20 and used for 20ml
reactions in SYBR1 Green PCR master mix (Applied Biosystems).
PCR and determination of the computed threshold was performed on
an iCycler (Bio-Rad). SOCS3 primers based on sequence NM_007707
are as follows: Right_AACTTGCTGTGGGTGACCAT, Left_
AAGGCCGGAGATTTCGCT.
STATISTICAL ANALYSIS
A two-tailed, homoscedastic t-test was used to calculate statistical
differences between control and experimental groups. Values are
reported as the mean standard deviation. P< 0.050 was consid-
ered statistically significant. For western blot, band density was
measured with UVP1 VisionWorksLSTM image acquisition and
analysis software. For Figures 1,5 and 6, SOCS3 band density was
normalized to GAPDH band density. For Figures 2 and 4, P-Stat3
band density was normalized to Stat3 band density. The resulting
value was then normalized to GAPDH. To evaluate significance, the
control ratio of [(P-Stat3/Stat3)/GAPDH] for each time point was set
to 1.0. The value from the corresponding ZA treated time point was
then assigned a proportional fraction of 1.0. This fraction was then
compared betweenmultiple independent blots, three to five blots per
time point, and statistics calculated as above.
RESULTS
ZOLEDRONIC ACID ENHANCES LEPTIN-INDUCED IL-6 PRODUCTION
IN AN ObRb TYR985-DEPENDENT MANNER
Primary BMMs from control and complete long-form leptin receptor
(ObRb) KO mice (Fig. 3A) were stimulated with 100 nM leptin
and 107–105M ZA (Fig. 3B). The conditioned medium was
subsequently analyzed for IL-6 and normalized to total genomic
DNA per well. ZA alone induced a 1.68 fold (P¼ 0.006) increase of
IL-6 in control cells and a 2.44-fold (P< 0.001) increase in KO cells
(Fig. 3B). Administration of 100 nM leptin induced a leptin-specific
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2.01-fold (P< 0.001) increase of IL-6 in control cells with no change
in ObRb KO cells confirming the ability of leptin to induce IL-6
through ObRb (Fig. 3B). Combination treatment with 105M ZA and
100 nM leptin produced a synergistic 5.78-fold (P< 0.001) increase
in IL-6 above that induced by ZA or leptin alone (Fig. 3B). This
synergy was not observed in the KO cells (Fig. 3B).
To determine which signaling pathway was responsible for the
increased cytokine production with combined leptin and ZA
treatment, we utilized two mouse models with gene targeted
deletions in the signaling components of the leptin receptor, ObRb.
ObRb has two signaling phosphotyrosines, Tyr1138 and Tyr985, on
the cytoplasmic domain of the receptor. Point mutation of Tyr1138,
which was generated in s/s gene targeted mice, blocks leptin
signaling through P-Stat3, and SOCS3. In contrast, mutation of
Tyr985 of the leptin receptor in l/l mice blocks 70–100%
of downstream Erk signaling [Myers, 2004]. The signaling deficits
of s/s and l/l mice have been previously verified in the central
nervous system [Bates et al., 2003; Bjornholm et al., 2007] and in
peripheral macrophages [Mancuso et al., 2011]. BMMs harvested
from s/s and l/l mice were genotyped (Fig. 3C) and treated as
described above. Repetition of the ELISA experiment revealed a
16.87-fold (P¼ 0.001) synergistic increase in IL-6 after combined
leptin and 105M ZA treatment in the s/s BMMs but not in the l/l
BMMs (Fig. 3D). This implies that synergistic induction of IL-6
production by Leptin and ZA requires Tyr985-directed Erk
signaling.
ZA BLOCKS SOCS3 PROTEIN ACCUMULATION BY BMMs
The s/s transgenic mice that lack the ability to signal through P-
Stat3 and SOCS3 demonstrated a robust synergistic increase in
macrophage IL-6 output. A similar increase was observed after
treatment of control macrophages with leptin and 105M ZA. Since
SOCS3 is a known inhibitor of leptin signaling, we hypothesized that
ZA may be regulating cellular SOCS3 accumulation. SOCS3 is a
negative-feedback regulator of signaling molecules such as leptin
and IL-6, and induction of SOCS3 expression can decrease
macrophage cytokine production [Yoshimura et al., 2007]. We
found that stimulation of BMMs with 20% FBS for 3 h increased
SOCS3 protein 1.8-fold (Fig. 1A). Treatment with 106 or 105M ZA
inhibited this increase in a dose dependent manner (Fig. 1A). Leptin
induction of SOCS3 protein levels by 2.4-fold at 3 h was also
inhibited dose dependently by 106 or 105M ZA (Fig. 1B).
Similarly, SOCS3 inhibition after stimulation with 25 ng/ml IL-6 by
ZA was noted (Fig. 1C).
ZA REDUCES PHOSPHORYLATION OF STAT3 IN A
MEVALONATE-PATHWAY DEPENDENT MANNER
Since SOCS3 RNA is induced by nuclear accumulation of P-Stat3
and previous reports have suggested that ZA can modulate P-Stat3
levels in clonal macrophages [Reuben et al., 2011], we investigated
the ability of ZA to regulate P-Stat3 in primary BMMs. Addition of
25 ng/ml IL-6 for 0–180min increased phosphorylation of Stat3
from 5–30min and again from 120–180min (Fig. 2A). Pre-
treatment with 105M ZA for 16–18 h resulted in both an increase
in total Stat3 at all time points and a reduction in Stat3
phosphorylation (Fig. 2B). This approximately 50% reduction in
Fig. 1. ZA inhibits SOCS3 protein accumulation in primary bone marrow
macrophages. Western blot densitometry data was normalized to GAPDH
control. A, B, C: ZA pretreatment for 16–18 h from 107–105M dose-
dependently inhibited induction of SOCS3 in BMMs by 20% serum, 100 nM
leptin, or 25 ng/ml IL-6, respectively after 3 h. Representative blots shown, all
experiments repeated at least twice.
Fig. 2. ZA inhibits Stat3 phosphorylation (A) Control western blot of
P-Stat3, Stat3, and GAPDH after BMM stimulation with 25 ng/ml IL-6 for
0–180min. B: Paired western blot after treatment with 105M ZA.
C: Statistical analysis of the ratio of phosphorylation of Stat3 after ZA
treatment to control at each time point (N¼ 3). Control densitometry ratio
[(P-Stat3/Stat3)/GAPDH] was set to 1.0 and corresponding ZA treated ratio
given a proportional value before statistical comparison of independent blots.
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the ratio of P-Stat3 to Stat3, normalized to GAPDH, was statistically
significant from 5–15min (Fig. 2C). Many of the functions of amino-
bisphosphonates are mediated by their ability to inhibit the
mevalonate pathway. Therefore, mevalonate pathway intermediates
GGOH and FOHwere added to determine the extent to which specific
intermediates may rescue the bisphosphonate-induced P-Stat3
defect. Addition of 10mM GGOH did not alter phosphorylation of
Stat3. In contrast, the addition of 10mM FOH fully restored levels of
P-Stat3 in the presence of 105M ZA (Fig. 4A).
CORRECTION OF P-STAT3 SIGNALING IS NOT SUFFICIENT TO
RESCUE SOCS3 PROTEIN INHIBITION
P-Stat3 nuclear accumulation induces SOCS3 mRNA transcription
[Banks et al., 2000]. Therefore, we sought to determine if cytokine
treatment had a similar effect in our system. Addition of 25 ng/ml
IL-6 significantly induced SOCS3 mRNA accumulation after 1 h
(data not shown). This increase was significantly blunted by
treatment with 105M ZA and rescued by concomitant treatment
with 10mM FOH, but not 10mM GGOH (Fig. 4B). Despite the
complete rescue of P-Stat3 protein and SOCS3 mRNA levels
(Fig. 4A, B), FOH at 5mM or 10mM was not sufficient to rescue
SOCS3 protein production (Fig. 5).
MACROPHAGE-ASSOCIATED SOCS3 LEVELS ARE DECREASED IN
HUMAN SPECIMENS
To determine if alterations in SOCS3 were present in human cells
and tissue, we analyzed both primary human macrophages and ONJ
biopsy specimens. hBMMs were harvested from iliac crest bone
marrow of a 60-year old male donor. Harvested cells were strongly
positive for CD68, a macrophage marker, when analyzed with
immunofluorescence (Fig. 6A). SOCS3 protein accumulation
induced after 5 h of 50 ng/ml IL-6 treatment was inhibited by
pre-incubation of the cells with 105M ZA (Fig. 6B) similar to
Fig. 3. ZA and leptin induce synergistic downstream cytokine production mediated by ObRb tyrosine 985. A: Genomic DNA PCR confirming complete cre-lox recombination of
the BMMs from the long-form leptin-receptor (ObRb) knock-out (KO) animals and intact ObRb in the controls. B: IL-6 ELISA of control and KO BMMs after 16–18 h
pretreatment with ZA followed by induction with 100 nM leptin for 24 h. C: Confirmatory genotyping of s/s (point mutation ObRb Tyr1138) and l/l (point mutation ObRb
Tyr985) mice. D: IL-6 ELISA of s/s and l/l BMMs as above. : Significant over NT control, : Significant over ZA only control. (N¼ 6, all experiments repeated at least twice)
Fig. 4. Farnesyl intermediates rescue ZA inhibition of P-Stat3 and SOCS3
mRNA. A: Western blot of BMMs pre-treated with 105M ZA and 10mM
GGOH or FOH overnight, ‘‘’’ indicates lack of ZA treatment. Pre-treated cells
were stimulated with 25 ng/ml IL-6 for 10–15min. Tabulated results report
the ratio of phosphorylation of Stat3 after ZA treatment to control at each
time point as in Figure 2 (N¼ 3). B: Quantitative PCR analysis of SOCS3 mRNA
after 1 h, treatments as in (B). Results are reported as percent of control SOCS3
mRNA (N¼ 3–5). : Significantly less than control.
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studies with mouse BMMs (Fig. 1A–C). Immunohistochemistry for
SOCS3 and CD68 was performed on serial sections of biopsies
derived from control human oral ulcerations or ulcerations
associated with ONJ. Comparison of SOCS3 staining density in
the areas of macrophage infiltration revealed a significant decrease
in SOCS3 in the ONJ specimens (16.8 16.2%, P¼ 001) when
compared to controls (70.5 27.1%) (Fig. 6C, D).
DISCUSSION
SOCS3 is an essential regulator of diverse cellular functions
including cytokine production and has been implicated in the
pathogenesis of inflammatory pathology such as Crohn’s disease
and rheumatoid arthritis. We found that the amino-bisphosphonate
ZA has the potential to enhance macrophage cytokine secretion by
inhibiting SOCS3 protein accumulation. Due to the extended half-
life of bisphosphonates and their ability to incorporate into the bone
matrix [Kozloff et al., 2010], it is possible that long-term systemic
persistence of these drugs may contribute to inflammatory
pathologic processes through the inhibition of SOCS3.
Indeed, ONJ, an increasingly recognized complication of amino-
bisphosphonate treatment, may be linked to altered macrophage
SOCS3 activity, as preliminary evidence suggests that SOCS3 protein
levels are decreased in ONJ biopsy specimens when compared to
controls. However, it is important to recognize a limitation of this
study. Except for specimen number 5 that contained a granulomatous
reaction (Fig. 6D), both the controls and the ONJ biopsy specimens
represented clinical ulcerations of similar appearance. In all specimens
one would expect to see an inflammatory reaction including induction
of SOCS3. However, the duration of the ulcers is unknown and their
Fig. 5. Rescue of P-Stat3 and SOCS3 mRNA with FOH does not correct
SOCS3 protein inhibition. Representative western blot of SOCS3 after ZA/
GGOH/FOH overnight pre-treatment where indicated and 3 h 25 ng/ml IL-6
stimulation of BMMs. GGOH and FOH concentrations are reported as mM and
combined with 105M ZA. Experiment was repeated three times with similar
results.
Fig. 6. Bisphosphonates decrease SOCS3 in human CD68þ macrophages and human ONJ biopsies. A: Cellular immunofluorescence of primary human macrophages.
Red¼ CD68, Blue¼Dapi. 40 magnification. B: Representative western blot of primary macrophage SOCS3 after treatment with 50 ng/ml IL-6 alone or IL-6þ 105M ZA.
Experiment was performed in duplicate with similar results. C: Representative serially stained sections of control ulcerated tissue and an ONJ lesion. 40 magnification.
D: Patient information, condition, treatment, and SOCS3 percent staining density.
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status as acute versus chronic inflammatory lesionsmay also influence
SOCS3 protein levels. Despite this level of information, the
approximately fourfold decrease in SOCS3 protein levels in the
ONJ specimens suggests that further investigation in this area may
provide additional insights on the mechanisms responsible for ONJ.
The pathogenesis of ONJ is currently unknown but may be linked
to decreased bone turnover, altered vascularity, bacterial invasion,
and compromised wound healing [Novince et al., 2009]. Osteoim-
munology is an emerging field of research that views regulation of
bone metabolism within the context of immune function [Lorenzo
et al., 2008]. While the macrophage has long been appreciated as a
key component of the immune system, an essential role for
macrophages in bone homeostasis was only recently confirmed
when induced depletion of macrophages in a mouse model ablated
mature osteoblast bone-forming surface [Chang et al., 2008].
In addition to regulation of osteogenesis, macrophage-released
cytokines are regulators of fibroblast and endothelial cell
proliferation and studies have speculated that reduced macrophage
infiltration may, in part, be responsible for increased rates of healing
of oral mucosa compared to keratinized dermal sites [Szpaderska
et al., 2003]. Thus, dysregulation of critical macrophage functions
such as cytokine production may contribute to altered bone
remodeling and decreased healing potential observed at sites of ONJ.
We found that ZA at concentrations of 106–105M is a novel
inhibitor of serum and cytokine-induced SOCS3 in macrophages in
vitro. Inhibition of SOCS3 was also observed in human ONJ biopsy
specimens in vivo. SOCS3 is a potent regulator of macrophage
responses to systemic cytokines such as IL-6 and leptin that are
upregulated in states of obesity. Analysis of alendronate release
kinetics in rat bone have demonstrated local bisphosphonate
concentrations of 103–104M at sites of active resorption after
0.4mg/kg treatment [Sato et al., 1991]. In addition, secreted
concentrations of 105M ZA are readily achieved with ZA-loaded
bone cement that has been proposed for local treatment of giant cell
tumor and multiple myeloma [Zwolak et al., 2010]. This study
reveals that the future use of such devices must consider
complications due to inhibition of SOCS3 and enhancement of a
destructive inflammatory response. Though our study has focused
on SOCS3 inhibition in the context of ONJ, this may also play
important roles in other inflammatory conditions such as rheuma-
toid arthritis [Isomaki et al., 2007], inflammatory bowel disease
[Suzuki et al., 2001], and Crohn’s disease [Lovato et al., 2003].
In summary, we conclude that ZA is a novel inhibitor of SOCS3
protein accumulation in macrophages, essentially ‘‘inhibiting the
inhibitor’’ of signaling by molecules such as leptin and IL-6 (Fig. 7).
Functionally, administration of ZA with leptin promoted a
synergistic induction of downstream IL-6 production by primary
BMMs that was not present in BMMs lacking the long-form leptin
receptor (ObRb). This effect was dependent on ObRb tyrosine 985,
likely mediated by the downstream Erk pathway (Fig. 7). Though ZA
was found to decrease both phosphorylation of Stat3 and initial
induction of SOCS3 mRNA in a mevalonate-pathway dependent
manner, rescue of these defects with FOH was not sufficient to
restore SOCS3 protein levels (Figs. 4 and 5). Thus, the specific
mechanism of SOCS3 inhibition is unclear at this point but may
involve a post-transcriptional process. Though this study focused on
SOCS3 induction by obesity-related cytokines leptin and IL-6, our
results suggest wider implications for regulation of additional
SOCS3 dependent signaling molecules such as IL-10, LPS and IFN-g.
In conclusion, we propose that inhibition of SOCS3 and dysregula-
tion of macrophage cytokine output may contribute to obesity-
associated inflammatory disorders and potentially the pathogenesis
of ZA-induced ONJ.
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